Information Provided By:
Fly News Breaks for February 27, 2015
MDXG
Feb 27, 2015 | 07:45 EDT
Canaccord noted MiMedx Q4 results exceeded its pre-announced numbers and the firm sees profitability continuing as a result of expanded distribution, continued market penetration, and market share gains. The firm sees new markets such as urology, gynecology and plastics gaining traction and leading to upside. Canaccord reiterated its Buy rating and $14 price target on MiMedx shares.
News For MDXG From the Last 2 Days
There are no results for your query MDXG
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.